Decision path
Use this article as the context layer.
Read the research framing, compare the relevant compounds, then use the quiz before moving into vendor or protocol decisions.
01
Read the context
02
Compare compounds
03
Take the quiz
04
Choose next step
Quick answer
Tirzepatide (Mounjaro / Zepbound) is a dual GLP-1 + GIP agonist and produces ~22% body-weight loss in trials versus ~15% for semaglutide (Ozempic / Wegovy). Tirzepatide tends to outperform on fat loss but is newer, more expensive, and has a similar side-effect profile.
Article next step
Turn this research into a personalized path.
Use the quiz before moving from education to compound, vendor, or protocol decisions.
Why this matters
These are the two most-searched GLP-1 compounds in 2026 and the most common starting point for fat-loss research.
Both compounds work, but they differ on average outcomes, side-effect intensity, dose escalation, and price.
Choosing between them without understanding the trade-offs leads to the wrong starting point and unnecessary side effects.
Key takeaways
Tirzepatide produced ~22% body-weight loss in SURMOUNT-1 vs. ~15% for semaglutide in STEP-1 — meaningful gap, but with overlap.
Both share the same GI side-effect profile (nausea, constipation, reflux); titration speed matters more than compound choice.
Tirzepatide is dual-action (GLP-1 + GIP), semaglutide is GLP-1 only — the dual mechanism is the leading hypothesis for the gap.
Cost-per-month is meaningfully higher for tirzepatide, especially at maintenance dosing.
Article protocol path
Move from article insight to protocol decision in five checks.
- 1
Baseline
Clarify goal, labs, contraindications, and sport/testing status.
- 2
Choose
Pick one primary compound path before stacking extras.
- 3
Source
Check vendor documentation, COA fit, and route constraints.
- 4
Monitor
Track outcomes, adverse effects, and stop conditions.
- 5
Reassess
Review whether the protocol still fits after the first cycle.
Weight loss results
The cleanest comparison comes from each compound's pivotal trial. Both used a similar patient profile, both ran 68–72 weeks.
Trial caveat
These are mean values with high individual variance. A meaningful share of participants in each trial lost less than the average, and a smaller share lost more.
Side effects
Both compounds share the same GI side-effect profile because the GLP-1 mechanism dominates upper-GI motility. The most common: nausea, constipation, diarrhea, reflux, and early satiety.
Side-effect intensity is mostly driven by titration speed, not compound choice. Skipping titration steps is the single biggest predictor of dropout in both populations.
Dosing & titration
Both compounds are once-weekly subcutaneous injections with stepped escalation.
| Compound | Starting dose | Maintenance dose | Titration interval |
|---|---|---|---|
| Semaglutide | 0.25 mg/wk | 1.7 – 2.4 mg/wk | Step every 4 weeks |
| Tirzepatide | 2.5 mg/wk | 5 – 15 mg/wk | Step every 4 weeks |
Cost
Tirzepatide's monthly cost typically runs higher than semaglutide at equivalent therapeutic doses, though pricing varies widely by source and region.
Compounded versions of both compounds have shifted the cost picture — but compounded supply is regulatorily fragile, and consumers should verify their source's licensing and testing practices.
Frequently asked questions
On trial averages, tirzepatide leads by roughly 7 percentage points. Individual response varies and either compound can outperform the other for a specific person.
Effectively the same profile. Tirzepatide has slightly higher reported GI events at top doses, but titration discipline matters more than compound choice.
Yes. Many researchers start on semaglutide and switch to tirzepatide if response plateaus, or move from tirzepatide to semaglutide for cost reasons at maintenance.
Semaglutide. It was first approved in 2017 (Ozempic) and 2021 for chronic weight management (Wegovy). Tirzepatide is newer (2022 / 2023).
Want this matched to your goals?
6 questions, 2 minutes. Free.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Use this breakdown to research smarter — then compare compounds, review vendor documentation, and take the quiz when you’re ready for a plan.